ornithine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ornithine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
An, X; Coonrod, SA; Li, F; Li, T; Liu, X; Miao, L; Muth, A; Qin, H; Thompson, PR; Xu, B; Zhang, X1
Forget, SM; Goralski, KB; Hall, SR; Jakeman, DL; Kerr, RG; MacLeod, JM; Overy, DP; Robertson, AW1

Other Studies

2 other study(ies) available for ornithine and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Cancer letters, 2017, 11-28, Volume: 409

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; HEK293 Cells; Humans; Hydrolases; MAP Kinase Kinase 1; MAP Kinase Signaling System; Matrix Metalloproteinase 2; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Ornithine; Protein-Arginine Deiminase Type 1; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays

2017
Isolation of a jadomycin incorporating L-ornithine, analysis of antimicrobial activity and jadomycin reactive oxygen species (ROS) generation in MDA-MB-231 breast cancer cells.
    The Journal of antibiotics, 2018, Volume: 71, Issue:8

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Isoquinolines; Microbial Sensitivity Tests; Ornithine; Reactive Oxygen Species; Staphylococcus; Streptomyces; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2018